NewsBenzingaTempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its... Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its... Benzinga 2026.10.23 13:11 (GMT+0) Open on Benzinga Other news LDP: The Family Favorite But Not Enough (NYSE:LDP) Betterware: Tupperware Looks Better, But Jafra Looks Worse (NYSE:BWMX) Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws Tower Semiconductor: The Silicon Photonics Opportunity Is Taking Shape (NASDAQ:TSEM) Enovis Screens Cheap, But There Is A Continued M&A Overhang (NYSE:ENOV) Coeur Mining: The Cost Trick Every Silver Investor Should Understand (NYSE:CDE)
Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws
